iTeos Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

Rhea-AI Summary

iTeos Therapeutics (ITOS) reported its Q4 and full year 2024 financial results, highlighting key developments in its immunotherapy pipeline. The company maintains a strong financial position with $655.0 million in cash, providing runway through 2027.

Key clinical milestones include anticipated topline interim data from GALAXIES Lung-201 in Q2 2025, featuring results from >240 patients, and interim datasets from GALAXIES H&N-202 and TIG-006 HNSCC trials expected in 2025. The company completed enrollment for the second dose cohort of EOS-984 + pembrolizumab combination trial.

Financial results show R&D expenses increased to $145.4 million for 2024 (vs $113.3M in 2023), while G&A expenses decreased to $49.1 million (vs $50.4M in 2023). Net loss widened to $134.4 million ($3.32 per share) for 2024, compared to $112.6 million ($3.15 per share) in 2023.

Positive

• Strong cash position of $655M providing runway through 2027
• Multiple clinical trial milestones expected in 2025
• Completed enrollment in second dose cohort of EOS-984 combination trial
• Reduction in G&A expenses to $49.1M from $50.4M YoY

Negative

• Net loss increased to $134.4M from $112.6M YoY
• R&D expenses rose 28.3% to $145.4M
• Loss per share widened to $3.32 from $3.15

Insights

Financial Analyst

iTeos Therapeutics' financial results reveal a company with solid financial footing but widening losses. The $655 million cash position (increased from $632.5M in 2023) provides substantial runway through 2027, covering multiple potential Phase 3 trials—a notable strength for a clinical-stage biotech.

However, the company's burn rate is accelerating with net losses increasing to $134.4 million for 2024 compared to $112.6 million in 2023. R&D expenses grew 28% to $145.4 million, reflecting expanded clinical trial activities, particularly for the belrestotug program including the GALAXIES Lung-301 Phase 3 trial.

The company's financial strategy appears focused on clinical advancement rather than near-term profitability, with several key data readouts positioned throughout 2025. The most significant catalyst is the topline interim data from GALAXIES Lung-201 expected in Q2 2025, which will include results from over 240 patients. This represents a critical inflection point that could validate their approach to immuno-oncology.

For investors, the extended cash runway provides valuable de-risking, allowing iTeos to weather potential setbacks in clinical development without immediate financing concerns. However, the increased net loss per share ($3.32 vs $3.15 in 2023) will likely pressure valuation until clinical validation emerges from the upcoming readouts.

Oncology Researcher

iTeos's pipeline shows strategic positioning across multiple immuno-oncology modalities with potential best/first-in-class assets. Their lead program, belrestotug (anti-TIGIT antibody), is progressing through a comprehensive clinical development strategy in collaboration with GSK—covering both NSCLC and HNSCC indications with multiple study arms.

The upcoming GALAXIES Lung-201 readout represents a important validation point for the anti-TIGIT approach, which has shown mixed results across the industry. This dataset will include critical biomarkers like ctDNA alongside traditional endpoints (ORR), potentially providing mechanistic insights beyond simple response data.

What differentiates iTeos's approach is their exploration of combination strategies, particularly the triplet with nelistotug (anti-CD96), targeting multiple immune checkpoints simultaneously. This reflects growing recognition that single checkpoint inhibition often provides insufficient activity in many patients.

Their earlier-stage assets show particular innovation: EOS-984's targeting of ENT1 addresses adenosine pathway immunosuppression through a novel mechanism, while the anti-TREM2 program (EOS-215) targets tumor-associated macrophages—an increasingly important therapeutic avenue as T-cell directed therapies show limitations.

From a development perspective, iTeos is efficiently advancing multiple programs simultaneously while maintaining financial discipline—a challenging balance in oncology drug development where each trial represents significant investment.

iTeos's Q4 and full-year 2024 results present a company at a critical development stage with widening losses but adequate financial cushion. The $655 million cash position provides runway through 2027, but this comes alongside concerning financial metrics – R&D expenses jumped 28.3% to $145.4 million and net losses increased to $134.4 million from $112.6 million in 2023. The accelerating quarterly burn rate (Q4 net loss of $43.7M versus $30.6M in Q4 2023) signals intensifying investment without immediate revenue prospects.

The company's clinical strategy centers on belrestotug, an anti-TIGIT antibody developed with GSK, which faces a pivotal moment with the GALAXIES Lung-201 readout in Q2 2025. This data represents the most significant near-term catalyst, though it's important to note that anti-TIGIT therapies have shown mixed results industry-wide, with several competitors experiencing setbacks.

iTeos is simultaneously advancing potentially differentiated assets – EOS-984 targeting the adenosine pathway through ENT1 inhibition and EOS-215 targeting tumor-associated macrophages via TREM2. These represent novel approaches in immuno-oncology but remain in early development.

For investors, this represents a classic biotech risk profile – significant cash runway but increasing losses without validated clinical assets. The company's valuation will likely remain pressured until key readouts provide efficacy validation, with the most meaningful inflection points still months away.

- Topline interim dataset from GALAXIES Lung-201 with >240 patients anticipated in 2Q25
- Interim datasets from GALAXIES H&N-202 and TIG-006 HNSCC with ~200 patients anticipated in 2025
- Completed enrollment of second dose cohort of EOS-984 + pembrolizumab combination in ongoing Phase 1 trial
- EOS-215 Phase 1 trial TRM-010 patient enrollment anticipated to begin in 2Q25
- Cash balance and investment balance of $655.0 million as of December 31, 2024 expected to provide runway through 2027

WATERTOWN, Mass. and GOSSELIES, Belgium, March 05, 2025 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today reported financial results for the fourth quarter and full year ended December 31, 2024 and provided a business update.

“Our team’s strong focus and execution over the last twelve months lay the groundwork for a potential breakthrough year for iTeos in 2025. As we advance multiple trials evaluating belrestotug + dostarlimab in collaboration with GSK, we look forward to the topline interim results from GALAXIES Lung-201 in the second quarter of 2025 as they will play a key role in shaping the next phase of our lead program’s development,” said Michel Detheux, Ph.D., president and chief executive officer of iTeos. “At the same time, we continue to accelerate two Phase 1 therapeutic candidates with best- or first-in-class potential that could fundamentally reshape the immuno-oncology field. With $655 million in cash and runway through 2027, we are poised to take bold steps forward to progress our innovative science and deliver novel therapies to those who need these most.”

Program Highlights

Belrestotug (EOS-448/GSK4428859A): IgG1 anti-TIGIT monoclonal antibody in development for the first-line treatment of locally advanced or metastatic PDL1-selected non-small cell lung cancer (NSCLC) and for the first-line treatment of PD-L1 positive recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) in collaboration with GSK. 

• GALAXIES Lung-301
  • Enrollment ongoing globally in randomized, double-blind Phase 3 registrational study assessing belrestotug + dostarlimab versus placebo + pembrolizumab in patients with first-line advanced, unresectable, or metastatic PD-L1 high NSCLC.

• GALAXIES Lung-201
  • Topline interim data from open label Phase 2 platform study assessing belrestotug + dostarlimab doublet and a triplet with GSK’s investigational anti-CD96 antibody, nelistotug, in first-line advanced / metastatic PD-L1 high NSCLC anticipated in 2Q25 to include safety, ORR, and ctDNA data from >240 patients, with pembrolizumab monotherapy ORR for 30 patients and PFS data from initial 124 patients treated. Data are expected to be submitted for presentation at a scientific congress in 2H 2025.

• GALAXIES H&N-202
  • Interim data from Phase 2 platform study assessing belrestotug + dostarlimab doublet and triplet with nelistotug in first-line patients with PD-L1 positive recurrent/metastatic HNSCC anticipated in 2025 to include safety and ORR from >150 patients.

• TIG-006 HNSCC
  • Topline data from the TIG-006 study in cohorts 2C & 2D assessing belrestotug + dostarlimab doublet in first-line PD-L1 positive advanced / metastatic HNSCC anticipated in 2025 to include safety, ORR, and PFS from a total of 42 patients.

EOS-984: Potential first-in-class small molecule in oncology inhibiting ENT1, a dominant transporter of adenosine involved in T cell metabolism, expansion, effector function, and survival.

• APT-008
  • Completed enrollment of the second dose cohort of the EOS-984 + pembrolizumab combination portion and continued advancement in the combination dose escalation of the Phase 1 trial in advanced malignancies.
  • Topline data assessing EOS-984 as a monotherapy and in combination with pembrolizumab in patients with advanced solid tumors anticipated in 2H25.
    

EOS-215: Potential best-in-class anti-TREM2 with a novel mechanism of action blocking monoclonal antibody targeting tumor-associated macrophages to reprogram the tumor microenvironment.

• TRM-010
  • Investigative New Drug (IND) application was submitted and allowed to proceed for a Phase 1 of EOS-215. Patient enrollment is anticipated in 2Q25.

Fourth Quarter and Full Year 2024 Financial Results

• Cash and Investment Position: The Company’s cash and investments position was $655.0 million as of December 31, 2024, as compared to $632.5 million as of December 31, 2023.The Company expects its cash balance to provide runway through 2027, which includes the potential initiation of multiple Phase 3 registrational trials assessing the belrestotug + dostarlimab doublet.
  
  
• Research and Development (R&D) Expenses: R&D expenses were $37.5 million and $145.4 million for the fourth quarter and year ended December 31, 2024, respectively, as compared to $27.9 million and $113.3 million for the same quarter and year ended in 2023, respectively. The increases compared to the comparative periods were primarily due to increases in activities related to the belrestotug program, including the launching of the GALAXIES Lung-301 Phase 3 trial. The increases were also due to increased activities relating to the EOS-984 and EOS-215 programs, and included the addition of new R&D employees hired to help advance these programs.
  
  
• General and Administrative (G&A) Expenses: G&A expenses were $11.8 million and $49.1 million for the quarter and year ended December 31, 2024, respectively, as compared to $12.4 million and $50.4 million for the same quarter and year in 2023, respectively. The decreases were primarily due to decreases in insurance expenses, recruiting expenses, and various other general and administrative expenses. These were partially offset by an increase in compensation and stock-based compensation expenses for G&A employees, and also an increase in professional fees.
  
  
• Net Income/Loss: Net loss was $43.7 million, or net loss of $1.01 per basic and diluted share for the quarter ended December 31, 2024, as compared to a net loss of $30.6 million, or a net loss of $0.85 per basic and diluted share for the quarter ended December 31, 2023. Net loss was $134.4 million, or net loss of $3.32 per basic and diluted share for the year ended December 31, 2024, as compared to a net loss of $112.6 million, or a net loss of $3.15 per basic and diluted share for the year ended December 31, 2023.
  

About iTeos Therapeutics, Inc.
iTeos Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients. iTeos Therapeutics leverages its deep understanding of tumor immunology and immunosuppressive pathways to design novel product candidates with the potential to restore the immune response against cancer. The Company’s innovative pipeline includes three clinical-stage programs targeting novel, validated immunosuppressive pathways designed with optimized pharmacologic properties for improved clinical outcomes, including the TIGIT/CD226 axis and the adenosine pathway. iTeos Therapeutics is headquartered in Watertown, MA with a research center in Gosselies, Belgium.

About Belrestotug (EOS-448/ GSK4428859A)
Belrestotug is an Fc active human immunoglobulin G1, or IgG1, monoclonal antibody (mAb) targeting T cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domains (TIGIT), an important inhibitory receptor which contributes to the suppression of adaptive and innate immune responses against cancer. As an optimized high-affinity, potent anti-TIGIT mAb, belrestotug is designed to enhance the antitumor response through a multifaceted immune modulatory mechanism by engaging with TIGIT and FcγR, a key regulator of immune responses which induces cytokine release and antibody dependent cellular cytotoxicity (ADCC). The therapeutic candidate is progressing in multiple indications in collaboration with GSK. 

About EOS-984
EOS-984 is a potential first-in-class small molecule targeting equilibrative nucleoside transporter 1 (ENT1) designed to inhibit the immunosuppressive activity of adenosine and restore immune cell proliferation. The therapeutic candidate has the potential to fully reverse the profound immunosuppressive action of adenosine on T and B cells and is in Phase 1 development.  

About EOS-215
EOS-215 is a potential best-in-class monoclonal antibody which antagonizes triggering receptor expressed on myeloid cells 2 (TREM2). The antibody is designed to block ligand binding and switch off the multiple tumor growth and survival promoting activities of tumor resident macrophages. EOS-215 has been shown preclinically to have a profound impact on macrophage function, promoting multiple anti-tumor mechanisms including T cell activation. The therapeutic candidate’s multiple mechanisms of action have been shown to translate to activity in highly immune resistant models and has completed IND-enabling studies.

Internet Posting of Information
iTeos routinely posts information that may be important to investors in the 'Investors' section of its website at www.iteostherapeutics.com. The Company encourages investors and potential investors to consult our website regularly for important information about iTeos.

Forward-Looking Statements
This press release contains forward-looking statements. Any statements that are not solely statements of historical fact are forward-looking statements. Words such as “believe,” “anticipate,” “plan,” “expect,” “will,” “may,” “intend,” “prepare,” “look,” “potential,” “possible” and similar expressions are intended to identify forward-looking statements. These forward-looking statements include statements relating to the potential benefits of our product candidates; the potential of our phase 1 product candidates to be best- or first-in-class and to fundamentally reshape the immuno-oncology field; the potential for iTeos to have a breakthrough year in 2025; iTeos being poised to take bold steps forward to progress its innovative science and deliver novel therapies to those who need these most; our plans and expected milestones, including having topline interim data from GALAXIES Lung-201 in 2Q25 that includes safety, ORR, and ctDNA data from > 240 patients, with pembrolizumab monotherapy ORR for 30 patients and PFS data from initial 124 patients treated, our expectation to submit data from GALAXIES Lung-201 for presentation at a scientific congress in 2H 2025, having interim data from GALAXIES H&N-202 in 2025 that include safety and ORR from a total of >150 patients, having topline data from the first portion of TIG-006 study in cohorts 2C & 2D in 2025 that include safety, ORR, and PFS from a total of 40 patients, having topline data from EOS-984 in 2H25, our expectation to start enrolling patients in TRM-010 in 2Q25; and our expectation that our cash balance and investment balance will provide runway through 2027.

These forward-looking statements involve risks and uncertainties, many of which are beyond iTeos’ control. Actual results could materially differ from those stated or implied by these forward-looking statements as a result of such risks and uncertainties. Known risk factors include the following: the expected benefits and opportunities related to the agreement between iTeos and GSK may not be realized or may take longer to realize due to a variety of reasons, including any inability of the parties to perform their commitments and obligations under the agreement, challenges and uncertainties inherent in product research and development and manufacturing limitations; success in preclinical testing and early clinical trials does not ensure that later clinical trials will be successful, and early results from a clinical trial do not necessarily predict final results; interim and early data may change as more patient data become available and are subject to audit and verification procedures; the data for our product candidates may not be sufficient for obtaining regulatory approval to move into later stage trials or to commercialize products; iTeos may encounter unanticipated costs or may expend cash more rapidly or more slowly than currently anticipated due to challenges and uncertainties inherent in product research and development and biologics manufacturing; iTeos may not be able to execute on its business plans, including meeting its expected or planned regulatory milestones and timelines, research and clinical development plans, and bringing its product candidates to market, for various reasons, some of which may be outside of iTeos’ control, including possible limitations of company financial and other resources, manufacturing limitations that may not be anticipated or resolved for in a timely manner, negative developments in the field of immuno-oncology, such as adverse events or disappointing results, including in connection with competitor therapies, and regulatory, court or agency decisions such as decisions by the United States Patent and Trademark Office with respect to patents that cover our product candidates; and those risks identified under the heading “Risk Factors” in iTeos’ Annual Report on Form 10-K for the period ended December 30, 2024 filed with the Securities and Exchange Commission (SEC) as well as other SEC filings made by the Company which you are encouraged to review. Statements regarding the Company’s cash runway do not indicate when or if the Company may access the capital markets.

Any of the foregoing risks could materially and adversely affect iTeos’ business, results of operations and the trading price of iTeos’ common stock. We caution investors not to place undue reliance on the forward-looking statements contained in this press release. iTeos does not undertake any obligation to publicly update its forward-looking statements other than as required by law.

For further information, please contact:

Investor Contact:
Carl Mauch
iTeos Therapeutics, Inc.
carl.mauch@iteostherapeutics.com

Media Contact:
media@iteostherapeutics.com

FAQ

What are the key clinical trial milestones for ITOS in 2025?

ITOS expects topline interim data from GALAXIES Lung-201 in Q2 2025 with >240 patients, and interim datasets from GALAXIES H&N-202 and TIG-006 HNSCC trials in 2025 with ~200 patients total.

How much cash does ITOS have and how long will it last?

ITOS has $655.0 million in cash as of December 31, 2024, expected to provide runway through 2027.

What caused ITOS's increased net loss in 2024?

The increased net loss was primarily due to higher R&D expenses ($145.4M vs $113.3M in 2023) from expanded clinical trial activities, particularly the GALAXIES Lung-301 Phase 3 trial.

What are the main programs in ITOS's clinical pipeline?

ITOS's main programs include belrestotug (anti-TIGIT antibody), EOS-984 (first-in-class ENT1 inhibitor), and EOS-215 (anti-TREM2 antibody targeting tumor-associated macrophages).